DoW Vision, Translational Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The FY26 Vision Research Program Translational Research Award (TRA), solicitation number HT942526VRPTRA, is a funding opportunity from the Defense Health Agency and Department of the Army designed to transform promising discoveries into new drugs, devices, or clinical practice guidelines. The program supports preclinical studies, clinical research, and pilot clinical trials, though full-scale clinical trials are explicitly excluded. Research must align with at least one FY26 VRP Focus Area and be ready for definitive testing in clinical trials by the end of the performance period. The maximum funding available is 1.6 million dollars for a performance period of up to three years, with awards expected to be made by September 30, 2027. The application process is a two-step sequence, beginning with a pre-application due July 28, 2026, followed by an invitation-only full application due November 12, 2026. Submissions are handled via eBRAP for intramural organizations and Grants.gov for extramural entities. A distinctive feature of the award is the Partnering Principal Investigator Option, which allows for an Initiating PI and a Partnering PI. Evaluation is conducted in two tiers: a peer review focusing on technical merit, research strategy, and feasibility, followed by a programmatic review assessing the project's relevance to military health and its contribution to the VRP portfolio. Teams developing new drugs or devices must include regulatory approval expertise, and all applicants must disclose foreign affiliations of key personnel.
General Info
Place of Performance
Not specifiedSet-Aside
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· If developing new drugs or device(s), the research team must include expertise in the regulatory approval process.
· The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.
· Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan.
· Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health.
· The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Department Of The Army -- Usamraa
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
